Drugs / RG7667
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01496755 | Jan 2012 → Jan 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG7667 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01496755 ↗ |
| Action | Inhibit | “inhibits its entry into host cells” PMID 26055360 ↗ Jun 2015 |
| Modality | Monoclonal antibody | “RG7667 is a unique combination of two monoclonal antibodies” PMID 26055360 ↗ Jun 2015 |
| Route | Intravenous | “RG7667 given intravenously” PMID 26055360 ↗ Jun 2015 |